AUSTIN, Texas—The hunt for an effective treatment for COVID-19 has led one team of researchers to find an improbable ally for their work: a llama named Winter. The team—consisting of researchers from The University of Texas at Austin, the National Institutes of Health and Ghent University in Belgium—reported their findings about a potential avenue for a coronavirus treatment involving llamas on May 5 in the journal Cell.
The researchers linked two copies of a special kind of antibody produced by llamas to create a new antibody that binds tightly to a key protein on the coronavirus that causes COVID-19. This protein, called the spike protein, allows the virus to break into host cells. Initial tests indicate that the antibody blocks viruses that display this spike protein from infecting cells in culture.
“This is one of the first antibodies known to neutralize SARS-CoV-2,” said Jason McLellan, associate professor of molecular biosciences at UT Austin and co-senior author.
The team is now preparing to conduct preclinical studies in animals such as hamsters or nonhuman primates, with the hopes of next testing in humans. The goal is to develop a treatment that would help people soon after infection with the virus.
“Vaccines have to be given a month or two before infection to provide protection,” McLellan explained. “With antibody therapies, you’re directly giving somebody the protective antibodies and so, immediately after treatment, they should be protected. The antibodies could also be used to treat somebody who is already sick to lessen the severity of the disease.”
This would be especially helpful for vulnerable groups such as elderly people, who mount a modest response to vaccines, which means that their protection may be incomplete. Healthcare workers and other people at increased risk of exposure to the virus can also benefit from immediate protection.
When llamas’ immune systems detect foreign invaders such as bacteria and viruses, these animals (and other camelids such as alpacas) produce two types of antibodies: one that is similar to human antibodies and another that’s only about a quarter of the size. These smaller ones, called single-domain antibodies or nanobodies, can be nebulized and used in an inhaler.
“That makes them potentially really interesting as a drug for a respiratory pathogen because you’re delivering it right to the site of infection,” noted Daniel Wrapp, a graduate student in McLellan’s lab and co-first author of the paper.
Winter, the llama who is at the center of all this, is 4 years old and still living on a farm in the Belgian countryside along with approximately 130 other llamas and alpacas. Her part in the experiment began in 2016 when she was about 9 months old and the researchers were studying two earlier coronaviruses: SARS-CoV-1 and MERS-CoV. In a process similar to humans getting shots to immunize them against a virus, she was injected with stabilized spike proteins from those viruses over the course of about six weeks.
Next, researchers collected a blood sample and isolated antibodies that bound to each version of the spike protein. One showed real promise in stopping a virus that displays spike proteins from SARS-CoV-1 from infecting cells in culture.
“That was exciting to me because I’d been working on this for years,” Wrapp said. “But there wasn’t a big need for a coronavirus treatment then. This was just basic research. Now, this can potentially have some translational implications, too.”
The team engineered the new antibody that shows promise for treating the current SARS-CoV-2 by linking two copies of the llama antibody that worked against the earlier SARS virus. They demonstrated that the new antibody neutralizes viruses displaying spike proteins from SARS-CoV-2 in cell cultures. The scientists were able to complete this research and publish it in a top journal in a matter of weeks thanks to the years of work they’d already done on related coronaviruses.
McLellan also led the team that first mapped the spike protein of SARS-CoV-2, a critical step toward a vaccine. (Wrapp also co-authored that paper along with other authors on the current Cell paper, including UT Austin’s Nianshuang Wang, and Kizzmekia S. Corbett and Barney Graham of the National Institute of Allergy and Infectious Diseases’ Vaccine Research Center.) Besides Wrapp, the paper’s other co-first author is Dorien De Vlieger, a postdoctoral scientist at Ghent University’s Vlaams Institute for Biotechnology (VIB), and the other senior authors besides McLellan are Bert Schepens and Xavier Saelens, both at VIB.
Edited from the original UT News article online here.